These findings suggested that elevated PLEK2 expression might contribute to suppressing antitumor immune responses within these malignancies, implicating PLEK2 in the modulation of tumor-immune interactions and potentially impacting the efficacy of immune-based therapies. The gene discussed is PLEK2; the disease is neoplasm.